HGS and Novartis's hepatitis C candidate Zalbin shows monthly dosing promise
This article was originally published in Scrip
Human Genome Sciences and Novartis have released interim Phase II data suggesting that monthly-dosing of their hepatitis C treatment candidate Zalbin (albinterferon alfa-2b) achieves comparable results to weekly dosing with Roche's Pegasys (peginterferon alfa-2a) – a current standard of care – in patients with genotypes 2 and 3 of the disease.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.